Celtic Biotech Iowa Licenses a Propitious Therapy for Acute and...

Celtic Biotech Iowa Licenses a Propitious Therapy for Acute and Chronic Nephropathy

By Healthcare Tech Outlook | Friday, November 30, 2018

WEST DES MOINES, IA: Spotlight Innovation – a provider of solutions for healthcare-focused companies, has announced that its subsidiary Celtic Biotech Iowa –a developer of novel clinical trial-phase therapeutic products for the treatment of cancers and pain in humans has entered into an exclusive, world-wide (excluding China) license agreement.

The agreement focuses on developing and marketing a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the immune processes that damage the kidneys. This will help to reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.


"This CKD therapy has shown the potential to improve kidney function in a variety of animal models, and we expect to see comparable effectivity as we move this therapy through the clinical trial process. For those people who have experienced kidney failure due to chronic kidney disease, there are currently only two options for treatment -- life-long dialysis or kidney transplant. We would hope that this therapy could be utilized to delay or stop the progression to dialysis or surgery,” says Dr. Paul Reid, President, Celtic Biotech Iowa.

Weekly Brief